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Clonal evolution in myelodysplastic syndromes
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Cancer development is a dynamic process during which the successive accumulation
of mutations results in cells with increasingly malignant characteristics. Here, we show the
clonal evolution pattern in myelodysplastic syndrome (MDS) patients receiving supportive
care, with or without lenalidomide (follow-up 2.5–11 years). Whole-exome and targeted deep
sequencing at multiple time points during the disease course reveals that both linear and
branched evolutionary patterns occur with and without disease-modifying treatment. The
application of disease-modifying therapy may create an evolutionary bottleneck after which
more complex MDS, but also unrelated clones of haematopoietic cells, may emerge.
In addition, subclones that acquired an additional mutation associated with treatment
resistance (TP53) or disease progression (NRAS, KRAS) may be detected months before
clinical changes become apparent. Monitoring the genetic landscape during the disease may
help to guide treatment decisions.
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M
yelodysplastic syndromes (MDSs) are a heterogeneous
group of haematopoietic neoplasms characterized by
abnormal differentiation, dysplasia and peripheral
blood cytopenias. Progression towards acute myeloid leukaemia
(AML) occurs in B30% of the patients. Various genetic
mutations underlying the pathogenesis of MDS have been
identiﬁed. Most of the recurrently affected genes can be classiﬁed
as transcription factors, signal transduction proteins, epigenetic
modiﬁers, proteins involved in RNA splicing and proteins of
the cohesin complex1–3. Typically, in a given MDS patient,
several mutations are present simultaneously. Various genes are
recurrently mutated in different individuals with MDS and likely
play a role in the pathogenesis of the disease (driver mutations),
but also random, nonpathogenic mutations that are acquired in
individual cells during life are found, as these are clonally
expanded together with the pathogenic mutations during the
development of the disease (passenger mutations)4. Oncogenesis
is thought to be a multistep evolutionary process. The successive
acquisition of several mutations that confer a selective advantage
may result in the emergence of populations of cells that harbour
the same set of mutations5,6.
Both linear and branching patterns of evolution have been
described. Linear evolution is characterized by the successive
appearance of dominant clones that overgrow their ancestral
clone after the acquisition of additional mutations. Branching
evolution is characterized by the emergence of different subclones
from one common ancestral clone, leading to the coexistence of
related (sub)clones that contain a partially overlapping set of
mutations7,8. The genetic diversity amongst these coexisting
subclones may result in a more difﬁcult to treat type of disease, as
some of the subclones may be resistant to speciﬁc types of
therapy.
Several studies have documented the genetic evolution in MDS
and AML5,9–14. Evolutionary patterns in MDS patients before or
without leukaemic transformation are, however, scarce and are
often based on the analysis of a limited number of samples per
patient. In this study, we performed an in-depth analysis of clonal
evolution in MDS patients who were followed over a prolonged
period of time. We show that both linear and branched
evolutionary patterns occur in MDS, and that clonal evolution
can be inﬂuenced by treatment.
Results
Genetic analysis of MDS patients. We assessed clonal evolution
by whole-exome sequencing (WES) followed by targeted deep
sequencing in 11 MDS patients (Table 1). T-cell DNA was used as
germline control. In addition, DNA from cultured mesenchymal
stromal cells (MSCs) was used as reference in ﬁve patients. Six
patients received supportive care (transfusions, growth factors)
only, whereas ﬁve patients also received lenalidomide. To capture
all mutations, WES was performed at the ﬁrst and last as well as
at several intermediate time points (n¼ 45). In addition, FLT3-
ITD was detected by fragment length analysis. Furthermore, in
speciﬁc cases, amplicon-based deep sequencing was used target-
ing a panel of genes recurrently mutated in myeloid malignancies
(Supplementary Tables 1 and 2). All identiﬁed mutations were
validated and quantiﬁed by targeted deep sequencing in all
available samples of each patient (on average 10,616 fold cover-
age). In 158 different genes, 176 different acquired somatic
mutations were identiﬁed (Supplementary Data 1). The median
number of acquired gene mutations was 17 (range 8–27) per
patient. Of these, a median of four mutations per patient
(range 0–6) were present in genes that have previously been
implicated in myeloid malignancies and are considered to be
driver mutations (Fig. 1a,c). The total number of genetic defects
detected in the ﬁrst sample of each patient correlated with the age
of the patient (P¼ 0.03, Fig. 1b), in line with the accumulation of
genetic alterations during ageing. The most frequent alterations
were nonsynonymous single-nucleotide variants (SNVs)
(n¼ 145, 82%) (Fig. 1d). Of all SNVs, 65% (n¼ 105) were
transitions, predominantly G:C-A:T (53%, Fig. 1e). Some
mutations were detected in all samples from a given patient,
whereas others were only seen at early or late time points, indi-
cating genetic evolution (Supplementary Fig. 1). No major
inﬂuence of therapy on the type of SNVs (transitions or trans-
versions) was observed when comparing early with late mutations
in the two different treatment groups (Supplementary Fig. 2).
Based on the variant allele frequencies (VAFs) at all available time
points (Supplementary Figs 3 and 4), mutations were clustered
and clonal composition and evolution patterns were recon-
structed (Figs 2 and 3). Results from high-density single-
nucleotide polymorphism (SNP) arrays (Supplementary Table 3)
and conventional cytogenetic analysis (Supplementary Data 2)
were taken along when reconstructing the clonal evolution.
Clonal evolution in patients treated with supportive care. Six
patients were treated with supportive care only, consisting of
transfusions and growth factors (erythropoiesis-stimulating
agents, granulocyte colony-stimulating factor and thrombopoie-
tin receptor agonist). In one of these patients (UPN04), just one
clone of MDS cells was observed, carrying 12 mutations including
3 mutations in recurrently mutated genes: one ZRSR2 mutation
and two different mutations in TET2 (Supplementary Data 1 and
Supplementary Fig. 3). The set of mutations carried by this clone
remained unchanged over the entire observational period of 8
years, during which the patient’s clinical condition remained
stable (Fig. 2a).
Two patients (UPN06 and UPN11) showed a linear evolution
pattern, in which successive clones, carrying increasing numbers
of mutations, overgrew their ancestral clones (Fig. 2b,c). In both
cases, concomitant with the emergence and expansion of a clone
harbouring a mutation in NRAS, the patient developed
leukocytosis (both 4100 109/l, for UPN06 after the last time
point) and progression of disease: UPN11 progressed from
RCMD (refractory cytopenia with multilineage dysplasia) to
RAEB-1 (refractory anaemia with excess blasts-1) and ultimately
developed secondary AML (sAML) (Fig. 2b), whereas UPN06
progressed from RARS (refractory anaemia with ringed
sideroblasts) towards RAEB-2 (Fig. 2c).
The other three patients who did not receive disease-modifying
treatment showed more complex, branching clonal evolution
patterns. In UPN03 (Fig. 2d), two divergent subclones emerged
from a common ancestral clone. Despite the genetic evolution,
the clinical condition of the patient did not evolve signiﬁcantly
over the 8 years of follow-up. Eventually, this patient died of
prostate cancer. The other two patients with branching evolu-
tionary patterns progressed towards sAML (Fig. 2e,f). In both
patients, mutations in RAS pathway members were observed.
In patient UPN05, a KRAS-mutated clone emerged. In patient
UPN07, two subclones, one carrying an NRAS mutation and one
carrying an RRAS mutation, were derived from a common
ancestral clone. The NRAS-mutated clone was dominant at the
time of ﬁrst sampling. Over time, this clone was gradually
outcompeted by subclones of the RRAS-mutated clone, with
concomitant progression to sAML.
Clonal evolution in patients treated with lenalidomide. Five
patients who received lenalidomide were analysed, four of whom
carried a deletion on chromosome 5q (Fig. 3). All four
5q patients responded well to lenalidomide (Fig. 3a–d), resulting
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in morphological and cytogenetic complete remission. However,
when considering the total set of somatically acquired mutations,
these four patients showed substantial differences with regard to
their clonal evolution patterns. Patient UPN01 (Fig. 3a) initially
showed a very good response to lenalidomide, and the MDS clone
was reduced to 2% of the bone marrow (BM) population. This
response was gradually lost during lenalidomide treatment, as a
descendant of the original clone carrying additional heterozygous
RELN and TP53 mutations slowly expanded, accompanied by a
gradual decline in haemoglobin levels. TP53 mutations are known
to be associated with lenalidomide resistance15.
In the other three 5q patients, distinct, nonrelated clonal
populations grew out during complete remission. These emerging
clones were already detectable at low levels before treatment
(Fig. 3 and Supplementary Data 3). In UPN08 and UPN09
(Fig. 3b,c), the MDS clones that dominated haematopoiesis before
the start of lenalidomide treatment diminished under treatment
to 0.2% and 2% of the bone marrow population, respectively
(Supplementary Data 2 and Supplementary Figs 3 and 4). In both
patients, however, genetically distinct clones emerged. To conﬁrm
that these expanding clones did not harbour any mutations that
were found in the previously detected dominant clones, we
performed colony assays (CFU-GEMM (colony-forming unit–
granulocyte, erythrocyte, monocyte and megakaryocyte)),
followed by sequencing of individually picked colonies. This
showed that the rising clones did not harbour any of the
mutations that were present previously (Fig. 4). In both patients,
del(5q)-containing clones were strongly suppressed by lenalido-
mide, but not completely eradicated. For example, in UPN08,
lenalidomide appeared to suppress all the clones present before
the start of lenalidomide treatment (containing, among others,
a CSNK1A1 mutation), but mutations remained detectable in
B0.4% of the cells during treatment (Supplementary Fig. 5).
In addition, in the remaining 5q patient, UPN10 (Fig. 3d),
clonal populations were still detectable during complete remis-
sion. Under lenalidomide treatment, cells carrying 5q and 8
other mutations with or without a monosomy 7 (Fig. 3d, red
and dark green clones) were strongly suppressed, but a
non-5q-deleted ancestral clone (dark blue clone, Fig. 3d) contain-
ing 6 mutations remained present. Under lenalidomide treatment,
subclones derived from this ancestral MDS clone expanded over
time. In addition, a JAK2 V617F containing clone expanded
under lenalidomide treatment (Fig. 3d and Supplementary Fig. 4).
Sequencing of single-cell-derived colonies showed that cells
harbouring this JAK2 mutation did never harbour mutations
present in the other subclones, indicating that the JAK2-mutated
cells represented a separate, unrelated clone (Fig. 4). After
4.5 years of treatment, the patient lost response to lenalidomide:
the haemoglobin levels gradually declined and the 5q clone,
which had been suppressed under lenalidomide, slowly expanded.
Because of clinical disease progression, lenalidomide treatment
was stopped and the patient underwent an allogeneic stem cell
transplantation. As a result, MDS cells were undetectable by
cytogenetic and ﬂuorescence in situ hybridization (FISH) analysis
for more than a year, although some patient-derived blood cells
could still be detected by quantitative donor–recipient chimerism
analysis (o1%, Supplementary Fig. 6). At 19 months after
transplantation, a clinical relapse was diagnosed in this patient,
with reappearance of the del(5q)-containing clone. Targeted
sequencing of a panel of 72 MDS driver genes revealed no
additional mutations at the time of relapse. However, 39 months
after transplantation, the MDS progressed to RAEB-1 and
additional karyotypic abnormalities and a CUX1 mutation were
observed. Upon relapse, the patient was treated with 5-azacitidine
for 8 months that led to a reduction in clone size (Fig. 3d)
accompanied by an improvement of haemogloblin levels.
The patient without a del(5q) (UPN02, Fig. 3e) received
lenalidomide for 16 months and had stable disease. After
discontinuation of lenalidomide treatment, the patient received
5-azacitidine for 1 year, resulting in a transient reduction in
transfusion frequency. Under this treatment a subclone contain-
ing several mutations, including a mutation in EZH2, expanded at
the expense of a subclone that was dominant before start of
5-azacitidine treatment (containing an SF3B1 and CUX1 muta-
tion). Interestingly, after 5-azacitidine treatment was stopped,
the EZH2-mutated clone disappeared, with concomitant reexpan-
sion of the SF3B1- and CUX1-mutated clone.
Clonal composition in different PB and BM cell fractions.
In MDS, the generation of mature blood cells from BM stem and
progenitor cells is disturbed, but not completely abrogated.
In theory, different mutations might occur in BM cells at different
stages of maturation. In addition, speciﬁc mutations might block
maturation at a particular stage, whereas others might allow
maturation up to completely mature blood cells. As a result,
diverse mutational landscapes may be observed in cells of
different progenitor cell fractions and maturation stages within a
Table 1 | Baseline patient characteristics.
UPN Sex Age Duration
of AHD
(months)
AHD type MDS
subtype
(FAB)
MDS
subtype
(WHO)
IPSS-R Transformation
to AML
Cause of death Cytogenetic
abnormalities
Follow
up
time
(years)
Sampling
moments
(n)
1 F 51 7 Anaemia RAEB RAEB-1 High No NA del5q, t(X;16) 11.2 19
2 M 62 7 Anaemia RARS RARS Very low No TBC NN 5.0 5
3 M 56 40 Anaemia RARS RARS Very low No Prostate cancer NN 7.7 6
4 M 66 43 Granulocytopenia RAEB RAEB-1 Low No NA NN 8.1 9
5 M 64 66 Thrombocytopenia RA RCMD Int Yes AML þ 8 7.0 6
6 M 58 6 Anaemia RARS RCMD Low No MDS/pneumonia þ 21 5.3 5
7 M 67 81 Pancytopenia RAEB RAEB-1 Int Yes AML NN 3.7 7
8 F 67 40 Anaemia,
Granulocytopenia
RAEB RAEB-1 Int No NA del5q, t(1;10) 11.3 13
9 F 73 69 Anaemia RA RA Low No Heart failure del5q, del9q 6.6 13
10 F 57 70 Thrombocytosis RA RCMD Int No NA del5q, del13q 9.3 31
11 M 67 0 NA RA RCMD Int Yes AML NN 2.4 6
AHD, antecedent haematological disease; AML, acute myeloid leukaemia; F, female; FAB, French–American–British classiﬁcation system; Int, intermediate; IPSS-R, Revised International Prognostic Scoring
System; M, male; NA, not applicable; NN, normal karyotype. RA, refractory anaemia; RAEB-1, refractory anaemia with excess blasts-1; RARS, refractory anaemia with ringed sideroblasts; RCMD, refractory
cytopenia with multilineage dysplasia; TBC, tuberculosis; UPN, unique patient number; WHO, World Health Organization classiﬁcation system.
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patient. To study this, we isolated DNA from various BM stem
(haematopoietic stem cells (HSCs)) and progenitor fractions
(common myeloid progenitor, granulocyte–macrophage pro-
genitor and megakaryocyte–erythroid progenitor) of six patients
(UPN01, 03, 04, 05, 06 and 10) at several time points in the
course of their disease. All mutations detected in the bulk of cells
were also detected in all analysed stem and progenitor fractions,
although sometimes with a somewhat different VAF in the var-
ious cell fractions (Fig. 5 and Supplementary Figs 7–9). In addi-
tion, mutations that arose later during the course of the disease,
being characteristic for developing subclones, were
present in all stem and progenitor cell fractions at roughly equal
frequencies. This suggests that both the early and late mutations
arose in early HSCs that are still capable of differentiation into
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Figure 1 | Genetic defects in 11 MDS patients. (a) Number of acquired mutations in 11 patients with MDS, as determined by whole-exome sequencing at
several time points (Supplementary Data 1) and conﬁrmed by amplicon-based deep sequencing. In light grey, the number of mutations in genes previously
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different myeloid lineages. In addition, the mutational burdens in
BM and peripheral blood (PB) samples were quite comparable
(Supplementary Figs 10–16). In general, the VAFs were some-
what lower in PB, likely caused by a higher percentage of
lymphoid cells. The PB granulocyte fraction exhibited compar-
able mutational burdens to BM samples, indicating that mutated
and nonmutated myeloid progenitor cells had a similar capacity
to form mature granulocytes.
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Discussion
We studied the mutational spectrum and clonal evolution in
MDS patients receiving supportive care, as well as in patients who
were treated with lenalidomide. Several patterns of clonal
evolution were observed ranging from a patient with a single
clone remaining stable for many years to patients with highly
dynamic shifts in clonal composition. We conﬁrmed that therapy
may inﬂuence clonal evolution and that MDS-unrelated clones
can arise under treatment14. Clonal evolution was observed in
both patients treated with lenalidomide and patients treated with
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branched evolution in UPN10. (e) Patient with a normal karyotype and without a major response to lenalidomide treatment. This patient shows a branching
evolutionary pattern, with a change in clonal composition under 5-azacitidine treatment. Vertical dashed lines indicate the investigated sampling moments.
The samples indicated with a triangle were analysed by WES. Subsequently, all samples were analysed with targeted deep sequencing. Only important
genetic aberrations are indicated; a full list of genetic aberrations can be found in Supplementary Figs 3 and 4, Supplementary Table 3 and Supplementary
Data 1 and 2. PCD, pentoxifylline, ciproﬂoxacin and dexamethasone.
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supportive care. Many patients in the supportive care group
received growth factors to stimulate haematopoiesis that might
have inﬂuenced the evolutionary pattern, but since we analysed
only a limited number of patients, we cannot draw any
conclusions. Three of the patients treated with growth factors
eventually progressed to sAML (UPN05, 07 and 11). In all three
patients, the clones that ultimately developed into sAML
contained a heterozygous mutation in one of the RAS family
members. Patient UPN05 and UPN11 acquired a mutation in
NRAS and KRAS respectively, that could be detected months
before sAML was diagnosed. In UPN07, two members of the RAS
pathway (NRAS and RRAS) were mutated in separate subclones.
RRAS mutations are not frequently found in haematological
malignancies, but some cases have been described16. One patient
with juvenile myelomonocytic leukaemia was reported who also
carried an NRAS and an RRAS mutation in separate clones,
whereas after chemotherapy only the RRAS-mutated clone
remained. In UPN07, the initial major clone containing an
NRAS mutation was outcompeted by the RRAS-mutated clone
over time. During this shift in clonal composition, no therapy
other than erythropoiesis-stimulating agent was given. Previous
reports have implicated RAS mutations in enhancement of
proliferation and progression towards sAML17–20. Together with
our data, this may indicate that screening for mutations in RAS
family members is warranted in MDS, as acquisition of these
mutations seems to correlate with the development of more
aggressive clones that eventually may result in progression
towards sAML. Ultimately, patients who acquire RAS mutations
might be candidates for speciﬁc forms of treatment that target the
RAS pathway or its downstream signalling partners, like MEK
inhibitors21.
The mechanism behind the beneﬁcial effect of lenalidomide in
patients harbouring a 5q deletion has recently been described22.
Lenalidomide stimulates the degradation of CSNK1A1 that leads
to apoptosis. MDS cells harbouring a deletion of 5q have only one
remaining CSNK1A1 allele, and are therefore thought to be more
sensitive to lenalidomide. Many patients eventually develop
resistance to treatment that is often accompanied by the
acquisition of TP53 mutations15,23. Patient UPN01 initially
showed an excellent clinical and molecular response to
lenalidomide, but gradually a subclone expanded that had
acquired a mutation in TP53. This mutation could not be
detected before treatment with lenalidomide (at a threshold of
0.2%). The increment of the TP53-mutated cells under
lenalidomide took considerable time, but eventually the patient
experienced recurrence of clinical symptoms. We can only
speculate whether intermittent treatment with lenalidomide
might have been more beneﬁcial than continuous treatment
(sufﬁcient enough to suppress the original TP53-negative clone,
while stalling the selection of the TP53-positive cells), or
detrimental (allowing both the TP53 negative and positive MDS
cells to grow). In case of the ﬁrst possibility, lenalidomide
sensitivity might have been preserved over a longer period of
time, but to address this, future clinical testing would be required.
UPN08 harboured a mutation in CSNK1A1 that is described to
be mutated in 5–18% of patients with a 5q deletion24–26. Although
the exact biological role of these mutations is still under
investigation, reports so far show a trend towards a decreased
response to lenalidomide and a decreased overall survival compared
with CSNK1A1 wild-type 5q patients24,25. In contrast, UPN08
showed a very good response to lenalidomide with a clinical and
cytogenetic complete remission maintained for already more than
8 years that might be related to the particular mutation (G24R) that
was found in this patient that has not been described before.
In four of the ﬁve patients who were treated with lenalidomide,
a signiﬁcant reduction of the total clone size was observed.
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Figure 4 | Sequencing of single-cell-derived colonies. To determine which mutations are present together in a single cell and to conﬁrm that cells from the
unrelated clones do not harbour any of the ancestral mutations present in the MDS clone, we performed sequencing on single-cell-derived CFU-GEMM
colonies. Representative mutations are sequenced from each (sub)clone. (a) UPN08: only colonies harbouring the two mutations linked to the unrelated
clone are found at this time point. The two investigated mutations from the MDS clone are absent in these colonies. (b) UPN09: most colonies only contain
an EIF3L mutation corresponding to the major unrelated clone. Two colonies harbour an additional CHRM2 mutation corresponding to a descendent of the
major unrelated clone. The mutations from the MDS clone are absent in these colonies. (c) UPN10: the JAK2 clone is an independent clone not containing
mutations from the major MDS clone. Furthermore, this analysis conﬁrms that LRRC34 is a descendent of the major MDS clone that later also acquired an
MLL2 mutation. The mutations in FRMD8, OCA2 and PRPS1L1 never co-occur with the LRRC34 and MLL2 mutations, indicating that these are separate
clones. The FRMD8 mutation appears to be a later event than the acquisition of OCA2 and PRPS1L1. The absence of a mutation (VAFo5%) is indicated in
grey. The presence of a mutation (VAF 440%) is indicated with a colour that corresponds to the clones in Fig. 3.
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Interestingly, in three of the responding patients, preexisting,
small clonal populations harbouring acquired mutations not
shared with the MDS cells grew out upon the reduction of
the number of MDS cells. In these patients, the application of
disease-reducing treatment may have created an evolutionary
bottleneck, after which repopulation may have occurred by a
limited number of HSCs harbouring preexisting mutations.
Similar observations have recently been described after induction
chemotherapy in AML27. The data suggest that several scenarios
may occur. Upon therapeutic reduction of the MDS clone a
pattern resembling clonal haematopoiesis of indetermined
potential may be observed, with clonal expansion of cells that
do not carry any known driver mutation (like in UPN08)28–30.
Furthermore, the reduction of the original MDS clone may create
space for the outgrowth of preexisting cells that carry well-known
driver mutations. This may lead to growth advantage during
recolonization of the bone marrow after therapy, like in patient
UPN10, in whom a JAK2-mutated clone expanded that did not
progress beyond a clone size of 20% and did not undergo further
genetic evolution. Finally, more proliferative and genetically
instable clones may grow out (like in patient UPN09) that still
may be derived from the initial MDS clone, but in which the early
common mutation was missed. Alternatively, these cells may
represent a second de novo MDS.
After 4.5 years of treatment, UPN10 gradually lost the response
to lenalidomide and underwent an allogeneic stem cell trans-
plantation. At 19 months after transplantation, one of the del(5q)
clones expanded, along with a clinical relapse. Interestingly, this
clone was genetically identical to one of the clones that originally
responded very well to lenalidomide. Therefore, the relapsing
clone might have been lenalidomide sensitive, and restarting
treatment might have been a valid option.
Two patients (UPN02 and UPN10) were treated with
5-azacitidine. In UPN02, the major clone decreased under
5-azacitidine treatment, whereas a subclone carrying an EZH2
mutation expanded. After 5-azacitidine treatment was stopped,
the EZH2-mutated subclone diminished and became undetect-
able, indicating that the EZH2-mutated subclone had a growth
advantage and the major clone was diminished under
5-azacitidine treatment. UPN10 showed an improvement of
haemogloblin levels and a reduction in clone size upon
5-azacitidine treatment. After 8 cycles the patient refused further
treatment due to her poor condition. After discontinuation of
5-azacitidine treatment, the MDS clone re-expanded. This
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Figure 5 | Percentage of MDS cells in various bone marrow stem and progenitor cell fractions. From six MDS patients with sufﬁcient material (UPN01,
03, 04, 05, 06 and 10), we sorted different bone marrow stem and progenitor cell fractions at various time points. Some minor differences in tumour
burden are observed between the various fractions. BL, baseline; HSC, haematopoietic stem cell; CMP, common myeloid progenitor; GMP, granulocyte–
macrophage progenitor; MEP, megakaryocyte–erythroid progenitor.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15099
8 NATURE COMMUNICATIONS | 8:15099 | DOI: 10.1038/ncomms15099 | www.nature.com/naturecommunications
observation is in contrast with the recently published data by
Merlevede et al.31, in which no decrease in clone size was
observed in monocytes from chronic myelomonocytic leukaemia
patients treated with hypomethylating agents.
The analysis of mutational burdens in various stem and
progenitor fractions indicates that in general, no gross differences
were observed between the different cell populations. This
suggests that both early and late MDS-associated mutations
originate in HSCs that are still capable of differentiation into the
various myeloid lineages, in line with the analysis of stem cell
fractions reported by Woll et al.13 In addition, the mutational
burdens in BM and PB were quite comparable. This suggests that
the more patient-friendly monitoring of patients on the basis of
peripheral blood is probably accurate32, comparable with the
monitoring of BCR-ABL levels in peripheral blood of chronic
myeloid leukaemia patients33.
Our study shows that various clonal evolution patterns can be
observed in MDS patients treated with and without disease-
modifying therapy. Monitoring of the genetic landscape during
the disease may help to guide treatment decisions.
Methods
Patient samples. Eleven MDS patients (7 males and 4 females) were selected
based on having a long disease course (2.5–11 years of follow-up, median 7) and
many sampling moments (5–31, median 7) (Table 1). Two categories of patients
were analysed: patients who received supportive treatment only (n¼ 6) and
patients who were treated with lenalidomide (n¼ 5). Two patients of the latter
group also received 5-azacitidine. BM and PB from these patients were obtained at
multiple time points. The study was conducted in accordance with the Declaration
of Helsinki and institutional guidelines and regulations from the Radboudumc
Nijmegen (IRB number: CMO 2013/064), and included informed consent by all
patients. The patient characteristics are listed in Table 1. Morphology of BM cells
was examined using standard May-Gru¨nwald-Giemsa stainings.
DNA isolation and ampliﬁcation. DNA was isolated from PB or BM of MDS
patients using the NucleoSpin Blood QuickPure kit (Macherey Nagel, Du¨ren,
Germany) according to the manufacturer’s protocol. In addition, BM and PB
mononuclear cells (MNCs) and PB granulocytes were obtained after Ficoll-1077
density gradient separation. BM or PB cells were slowly added on top of a layer
with Ficoll-Paque PLUS (density 1.077) (GE Healthcare, Chicago, IL, USA). After
centrifugation at 700 g for 20min, MNCs were present on top of the Ficoll layer
and granulocytes (and red bloods) underneath. These two cell fractions were
collected separately, after which DNA was isolated. When the extraction yield was
insufﬁcient (o5 mg) as measured with the Qubit ﬂuorometer Quant-iT dsDNA BR
Assay Kit (Thermo Fisher Scientiﬁc, Waltham, MA, USA), 80 ng of DNA was
ampliﬁed using the Qiagen REPLI-g kit (Qiagen, Venlo, The Netherlands) in
4 parallel reactions (20 ng per reaction), according to the manufacturer’s protocol.
Karyotype analysis. Bone marrow samples were cultured for
24–48 h in RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) supple-
mented with 10% fetal calf serum and antibiotics. After hypotonic treatment with
0.075M KCl and ﬁxation in methanol/acetic acid (3:1), microscopic slide
preparations were prepared. Chromosomes were G-banded using trypsin
(Life Technologies) and Giemsa and at least 20 metaphases were analysed in case of
a normal karyotype, and at least 10 in case of an abnormal karyotype. Karyotypes
were described according to the standardized ISCN 2013 nomenclature system34.
Fluorescence in situ hybridization. Standard cytogenetic cell preparations were
used for FISH. FISH was performed using commercially available probe kits for LSI
EGR1/D5S23D5S721, LSI IGH/MYC/CEP 8 and D13s319/13q34 FISH, according
to the manufacturer’s speciﬁcations (Abbott Molecular, Des Plaines, IL, USA).
Fluorescent signals of at least 200 interphase nuclei were scored and interpreted by
two independent investigators. The cutoff values for both gains and losses were
determined by statistical evaluation of FISH results from control tissue. For each
probe the meanþ 3 s.d. of false positive nuclei was taken as the cutoff level.
T-cell culture. Pure T cells were obtained from each patient by in vitro expansion
of T cells from PB (or BM). Monocytes were ﬁrst depleted by adherence to tissue
culture ﬂasks. The remaining cells were cultured for 14 to 21 days in IMDM
medium (Life Technologies) supplemented with 10% human serum (PAA
Laboratories GmbH, Pasching, Austria), interleukin-2 (100 IUml 1) and
CD3/CD28-coated Dynabeads (Thermo Fisher). The purity of the T cells was
measured by ﬂow cytometric analysis using the CD3 surface marker. When the
purity of the T cells exceeded 95%, DNA was isolated using the NucleoSpin Blood
QuickPure kit.
Mesenchymal stromal cell culture. MSC lines were generated from ﬁve subjects.
Bone marrow MNCs were obtained by Ficoll-1077 density gradient separation.
BM-MNCs were seeded at a density of 8 to 23 104 cells cm 2 in a-MEM
medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with heparin
(3.5 IUml 1) and 5% platelet lysate. Platelet lysate was prepared by freeze-thawing
of platelets (40.8 109 platelets per ml), followed by centrifugation at 4,700 g and
collection of the supernatant. At 7 days after seeding, the culture medium was
refreshed. Subsequently, cells were passed when 80% conﬂuency was reached. After
7 days of culture, all ﬂoating and dead cells were washed away and a layer with
MSCs remained. MSCs were cultured for up to 5 passages.
CFU-GEMM culture and sequencing of single colonies. PB-MNCs or
BM-MNCs were seeded in methylcellulose media (10,000–25,000 cells per ml for
BM and 100,000–200,000 cells per ml for PB) containing stem cell factor, inter-
leukin-3, granulocyte–macrophage colony-stimulating factor and erythropoietin
(H4434; Stem Cell Technologies, Vancouver, Canada) and incubated for 14 days at
37 C with 5% CO2. Individual colonies were collected on day 14 and washed with
phosphate-buffered saline in a 96-well plate. Cells were lysed by adding 30 ml lysis
buffer (TE-bufferþ 0.5% Igepal-CA630þ 0.6 ml proteinase K (10mgml 1)) fol-
lowed by incubating at 56 C for 120min and at 90 C for 30min. Subsequently,
1 ml of the lysate was used for each PCR reaction. Targeted amplicon-based deep
sequencing was performed as described below. To exclude the possibility of
reporting the results of mixed colonies, only colonies in which mutations were
detected with a VAF of 440% were reported as positive.
Sorting of myeloid progenitors. 1ml viably frozen bone marrow MNCs were
thawed in the presence of 100ml DNAse I (2mg ml 1) and incubated for 10min in
a solution of 1.6ml fetal calf serum, 10 ml heparin (5,000 Uml 1) and 100ml
MgSO4 (0.22 mM). Subsequently, the myeloid progenitor cells were sorted
according to a protocol adapted from Pang et al.35 The cells were washed and
stained with CD34-APC (Beckman Coulter, Brea, CA, USA), CD38-PE-Cy7
(BioLegend, San Diego, CA, USA), CD123-PE (BioLegend) and CD45RA-PB
(BioLegend) monoclonal antibodies. Cells were analysed and sorted using a FACS
Aria SORP ﬂow cytometer and DIVA software (Becton Dickinson, Franklin Lakes,
NJ, USA). Viable cells were selected based on forward scatter and side scatter
proﬁles, and doublets were discriminated using forward scatter area versus width
and side scatter area versus width. The HSC population was deﬁned as
CD34þCD38 . Within the CD34þCD38þ fraction, the common myeloid
progenitor cells (CD123þCD45RA ), the granulocyte-macrophage progenitor
cells (CD123þCD45RAþ ) and the megakaryocyte-erythroid progenitor cells
(CD123CD45RA ) were selected. DNA isolation from these cell fractions,
followed by DNA ampliﬁcation, was carried out using the Qiagen REPLI-g single
cell kit (Qiagen) according to the manufacturer’s protocol.
Whole-exome sequencing. WES to an average depth of 110 was performed on
sequential BM-MNC (n¼ 43) and PB-MNC samples (n¼ 2) taken at regular time
intervals (2 to 8 samples per patient). For all patients, DNA isolated from cultured
T cells was used as a constitutive reference to exclude germline variants. Mutations
signiﬁcantly higher in the tumour cells than the T cells were listed as high con-
ﬁdence mutations and taken along in our analysis. In both, UPN02 and UPN03
one mutation was clearly affecting the T cells (VAF 19% and 24% respectively, see
Supplementary Data 1), but in both cases the VAF was signiﬁcantly higher in the
tumour sample. Furthermore, for ﬁve patients DNA was available from cultured
MSCs and used as additional germline control to ensure that no variants acquired
in multipotent HSCs (and therefore also affecting T cells36) were incorrectly
marked as germline variants and excluded. No MDS-associated mutations were
found in the T cells of these ﬁve patients (Supplementary Table 4), indicating that
the T cells were not part of the malignant clone.
Exome capture was performed using SureSelect Human All Exon V5 (Agilent
Technologies, Santa Clara, CA, USA). Enriched exome fragments were then
subjected to massively parallel sequencing using the HiSeq 2500 platform
(Illumina, San Diego, CA, USA). Sequence alignment and mutation calling were
performed using our in-house pipelines, as previously described37, with minor
modiﬁcations. Candidate mutations with (1) Fisher’s exact Pr0.001 and (2) a VAF
in tumour samples Z0.07 (to reduce false positive mutation calls) were selected.
These variants were further ﬁltered by excluding (1) synonymous SNVs, (2) SNVs
in genes whose structure is not correctly annotated (complete open reading frame
information is not available) and (3) SNVs listed as SNPs in the 1000 Genomes
Project database (Nov 2010 release), dbSNP131 or our in-house SNP database.
High-density SNP arrays were performed on DNA extracted from BM cells at
several time points, allowing to correct VAFs for local copy number variations.
Targeted deep sequencing using gene panels. For one patient we analysed
2 samples collected after allogeneic stem cell transplantation using SureSelect
(Agilent)-based targeted-capture sequencing for 72 known MDS driver genes
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(Supplementary Table 2). Mutation calling was performed as previously described3,
with minor modiﬁcations. Germline SNVs were removed using WES data of paired
germline control samples. Finally, we selected only mutations considered to be
deﬁnitely oncogenic2. In addition, we used a myeloid gene panel (Trusight,
Illumina) (Supplementary Table 1) to screen for driver mutations in unrelated
clones.
Targeted amplicon-based deep sequencing. The candidate somatic variants
detected by WES were validated and quantiﬁed by amplicon-based deep sequen-
cing on an Ion Torrent Personal Genome Machine (Thermo Fisher Scientiﬁc) at
high depth (aim 10,000 coverage). Using this approach, mutational burdens
were measured in all available PB and BM samples for each patient (Supplementary
Data 3). Fragments with lengths of B200 base pairs were ampliﬁed in two
consecutive PCR reactions, PCR1 and PCR2, both of which were performed using
Q5 Hot Start High-Fidelity Master Mix (New England Biolabs, Ipswich, MA, USA)
according to the manufacturer’s protocol. In PCR1, the target fragments were
ampliﬁed and tagged with common sequence (CS)-tags (designed by Fluidigm,
South San Francisco, CA, USA). For this purpose, sequence-speciﬁc primers were
designed to obtain PCR fragments of B200 base pairs. CS-tags were attached to
these primers (see Supplementary Fig. 17 for primer strategy and Supplementary
Tables 5 and 6 and Supplementary Data 4 for primer sequences). Depending on
the primer pair, the best of three optimized touchdown PCR protocols was used
(see Supplementary Table 7). In PCR2, primers containing a CS-tag, a barcode and
an adapter (see Supplementary Fig. 17 for primer strategy and Supplementary
Tables 5 and 6, and Supplementary Data 4 for primer sequences), were used to
label the PCR fragments with a sample-speciﬁc Ion Xpress barcode (designed by
Thermo Fisher Scientiﬁc) and add the adapters required for emulsion PCR. The
second PCR was performed twice, once with the A adapter attached to the forward
primer and the truncated P1 (trP1) adapter to the reverse primer (PCR2-A) and
vice versa (PCR2-B), making bidirectional sequencing possible. For the PCR
protocol for PCR2 see Supplementary Table 8. Subsequently, PCR products were
pooled and puriﬁed with Agencourt AMPure XP beads (Beckman-Coulter,
Fullerton, CA, USA) to eliminate primer dimers. After puriﬁcation, the purity of
the pool (based on expected fragment size) was measured on the Agilent 2200
TapeStation (Agilent Technologies) using the high-sensitivity D1000 ScreenTape
assay (Agilent). The puriﬁed pool was diluted to 3 pg ml 1 and loaded onto the Ion
OneTouch system (Thermo Fisher Scientiﬁc) for emulsion PCR using the Ion PGM
Template OT2 200 kit (Thermo Fisher Scientiﬁc), followed by an enrichment for
loaded Ion Sphere Particles (ISPs). The quality of the enriched ISPs was checked
with the Ion Sphere Quality Control Kit (Thermo Fisher Scientiﬁc) on the Qubit
Fluorometer (Thermo Fisher Scientiﬁc). Subsequently, the ISPs were loaded onto
an Ion 314, 316 or 318 v2 Chip (Thermo Fisher Scientiﬁc) and sequenced using the
Ion PGM Sequencing kit v2 (Thermo Fisher Scientiﬁc) on the Ion Torrent Personal
Genome Machine system (Thermo Fisher Scientiﬁc). All steps were performed
according to the manufacturer’s protocols. The sequencing data were mapped to
the GRCh37 (hg19) reference genome build and variants were called with the
SeqNext module of the Sequence Pilot software, version 4.2.2 (JSI Medical Systems,
Ettenheim, Germany). Besides the automatic calling of variants, all locations
wherein variants were detected by WES were manually inspected. A mutation was
marked as validated by targeted deep sequencing when detected in the tumour
sample (which was also used for WES) with a higher VAF than in the germline
sample (at least 5% difference). The median validation rate per patient was 66.7%.
Most mutations that could not be validated were mutations detected by WES in an
ampliﬁed DNA sample (mainly insertions or deletions of a C or G), or mutations in
genes that have a highly identical family member (likely incorrect mapping of WES
reads). To determine an optimal cutoff VAF to discriminate true mutations from
sequencing noise, we determined the sensitivity and speciﬁcity of Ion Torrent
targeted deep sequencing. When we analysed the presence of 8 different mutations
in 10 healthy donors, a VAF cutoff of 0.2% resulted in a speciﬁcity of 100%
(Supplementary Table 9). In addition, we made a dilution series of 3 different SNPs
and observed that a VAF of 0.1% could still accurately be detected (Supplementary
Table 10). Based on this, we used a cutoff of 0.2%, which means 20/10,000 reads
should harbour the mutation. In addition, the mutated base had to be the second
highest base at the investigated position. This ensures that also in a more difﬁcult
sequence context the mutation exceeds the sequencing noise. In addition, a FLT3-
ITD mutation was detected using fragment length analysis.
Microarray-based genomic proﬁling (SNP array). Microarray-based genomic
proﬁling was carried out using the CytoScan HD array platform (Affymetrix, Inc.,
Santa Clara, CA, USA). Hybridizations were performed according to the manu-
facturer’s protocols. The data were analysed using the Chromosome Analysis Suite
software package (Affymetrix), using the annotations of reference genome build
GRCh37 (hg19). For a comprehensive analysis of the microarray-based genomic
proﬁling data, we used a previously developed ﬁltering pipeline. The interpretation
was performed using criteria adapted from Simons et al.38 and Schoumans et al.39
First, all aberrations affecting segments larger than 5Mb (resolution of conventional
karyotyping), regardless of gene content, were denoted as true aberrations.
In addition, all aberrations affecting segments smaller than 5Mb that coincided with
known cancer genes (http://cancer.sanger.ac.uk/cancergenome/projects/census/,
date of accession November 2012) were included. Since paired control DNA was not
used, alterations that coincided with established normal genomic variants were
excluded. For this approach, we used the publicly available ‘Database of Genomic
Variants’ (http://projects.tcag.ca/variation) and, in addition, in-house databases of
copy number alterations (CNAs) detected inB1,000 healthy individuals studied with
the CytoScan HD platform. Regions of copy-neutral loss of heterozygosity, also
known as acquired uniparental disomy, were only considered if they were410Mb in
size and if they extended towards the telomeres of the involved chromosomes, as
reported by Heinrichs et al.40 Finally, focal CNAs in the immunoglobulin and T-cell
receptor genes were excluded from this study, as these CNAs generally represent the
rearranged T-cell receptor and immunoglobulin genes present in the PB lymphocytes
of the normal reference samples. All the data were also visually inspected to deﬁne
alterations present in smaller proportions of cells and to eliminate alterations reported
in regions with low probe density. Only aberrations fulﬁlling the above criteria were
included in the genomic proﬁles and were described according to the standardized
ISCN 2013 nomenclature system34.
Reconstructing clonal composition and evolution patterns. Various software
tools were tested to analyse clonal composition and evolution. However, different
programs yielded different results, and close manual inspection showed imper-
fections in the patterns generated by all tested programs. Therefore, we constructed
the clonal evolution patterns based on VAFs of all detected mutations at all time
points, and included information from karyotyping, FISH and SNP arrays. For
clonal reconstruction, all variants detected with a VAF ofZ0.2% were considered.
Mutations were clustered based on the VAFs (corrected for ploidy) from all
sequenced samples (PB and BM) at all different time points. The sequential order
of mutational events and the most probable clonal evolution pattern were derived
from these mutation clusters and their behaviour in time.
In UPN05, the clonal evolution pattern was calculated for the mononuclear
myeloid cell fraction, rather than for the total BM-MNC fraction, as this
patient developed bone marrow ﬁbrosis and PB lymphocytosis, resulting in
noncomparable sampling before and during treatment with romiplostim. In all
other patients, lymphocyte counts were stable over time.
Data availability. Sequencing data (fastq ﬁles) of all 11 patients have been
deposited into the NCBI Sequence Read Archive under accession number
SRP094064. All other remaining data are available within the Article and
Supplementary Files, or available from the authors on request.
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